General Information of the m6A Target Gene (ID: M6ATAR00107)
Target Name Urothelial cancer associated 1 (UCA1)
Synonyms
UCA1; urothelial cancer associated 1 (non-protein coding); LINC00178; CUDR; UCAT1; onco-lncRNA-36; long intergenic non-protein coding RNA 178; cancer up-regulated drug resistant
    Click to Show/Hide
Gene Name UCA1
Chromosomal Location 19p13.12
Family Long non-coding RNAs with non-systematic symbols
Gene ID 652995
HGNC ID
HGNC:37126
Ensembl Gene ID
ENSG00000214049
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
UCA1 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) [READER]
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary Urothelial cancer associated 1 (UCA1) increases KRAS phosphorylation by interacting with hnRNPA2B1 and that UCA1 functions as a molecular sponge for miR-590-3p to promote KRAS expression. the UCA1-KRAS axis plays a crucial role in pancreatic ductal adenocarcinoma progression and that UCA1 serves as a target for new PDAC therapies.
Target Regulation Up regulation
Responsed Disease Pancreatic ductal adenocarcinoma ICD-11: 2C10.0
Pathway Response Ras signaling pathway hsa04014
In-vitro Model HPDE6c7 Normal Homo sapiens CVCL_0P38
HEK293T Normal Homo sapiens CVCL_0063
HPAF-II Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0313
MPanc-96 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_7165
PANC-1 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
PaTu 8902 Pancreatic adenocarcinoma Homo sapiens CVCL_1845
PaTu 8988s Pancreatic adenocarcinoma Homo sapiens CVCL_1846
SW1990 Pancreatic adenocarcinoma Homo sapiens CVCL_1723
In-vivo Model HPAF-II cells (2.0 × 106 cells/site) stably transfected with sh-EGFP or sh-UCA1 were subcutaneously injected into 4-week-old nude mice to generate xenografts. The tumor volume was measured every week after injection and calculated using the following formula: length × (width2)/2.
Pancreatic cancer [ICD-11: 2C10]
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary Urothelial cancer associated 1 (UCA1) increases KRAS phosphorylation by interacting with hnRNPA2B1 and that UCA1 functions as a molecular sponge for miR-590-3p to promote KRAS expression. the UCA1-KRAS axis plays a crucial role in pancreatic ductal adenocarcinoma progression and that UCA1 serves as a target for new PDAC therapies.
Responsed Disease Pancreatic ductal adenocarcinoma [ICD-11: 2C10.0]
Target Regulator Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) READER
Target Regulation Up regulation
Pathway Response Ras signaling pathway hsa04014
In-vitro Model HPDE6c7 Normal Homo sapiens CVCL_0P38
HEK293T Normal Homo sapiens CVCL_0063
HPAF-II Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0313
MPanc-96 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_7165
PANC-1 Pancreatic ductal adenocarcinoma Homo sapiens CVCL_0480
PaTu 8902 Pancreatic adenocarcinoma Homo sapiens CVCL_1845
PaTu 8988s Pancreatic adenocarcinoma Homo sapiens CVCL_1846
SW1990 Pancreatic adenocarcinoma Homo sapiens CVCL_1723
In-vivo Model HPAF-II cells (2.0 × 106 cells/site) stably transfected with sh-EGFP or sh-UCA1 were subcutaneously injected into 4-week-old nude mice to generate xenografts. The tumor volume was measured every week after injection and calculated using the following formula: length × (width2)/2.
References
Ref 1 The UCA1/KRAS axis promotes human pancreatic ductal adenocarcinoma stem cell properties and tumor growth. Am J Cancer Res. 2019 Mar 1;9(3):496-510. eCollection 2019.